Neoadjuvant immunotherapy for patients with non-small cell lung cancer-current evidence.

Ann Transl Med · 2020 · PMC7729370 · PMID 33313221

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

In their report, out of 37 patients who had evaluable pathology, 15 (41%) had MPR, all of whom had SCC, with a strong trend favoring response for SCC compared to adenocarcinomas.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.